Trial Profile

Long-term retension of abatacept versus TNFi in patients with rheimatoid arthritis with first biological DMARD failure

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abatacept (Primary)
Indications Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use

Most Recent Events

08 Nov 2017 Results assessing the long-term retention of abatacept and TNF inhibitor (TNFi) following first biologic (b)DMARD inadequate response in RHUMADATA registry patients with RApresented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
06 Jul 2017 New trial record
17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com